Abstract
BackgroundDenosumab (DMAb) reduces bone turnover in transiliac crest bone biopsies, which is reversible on treatment cessation (Reid JBMR 2010; Brown JBMR 2011). Long-term DMAb treatment sustains reduction in bone turnover...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have